These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22918775)

  • 1. Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry.
    Hörsch D; Ezziddin S; Haug A; Gratz KF; Dunkelmann S; Krause BJ; Schümichen C; Bengel FM; Knapp WH; Bartenstein P; Biersack HJ; Plöckinger U; Schwartz-Fuchs S; Baum RP
    Recent Results Cancer Res; 2013; 194():457-65. PubMed ID: 22918775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up.
    Hörsch D; Ezziddin S; Haug A; Gratz KF; Dunkelmann S; Miederer M; Schreckenberger M; Krause BJ; Bengel FM; Bartenstein P; Biersack HJ; Pöpperl G; Baum RP
    Eur J Cancer; 2016 May; 58():41-51. PubMed ID: 26943056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Somatostatin receptor endoradiotherapy of neuroendocrine tumors: experience in Hungarian patients].
    Reismann P; Kender Z; Dabasi G; Sréter L; Rácz K; Igaz P
    Orv Hetil; 2011 Mar; 152(10):392-7. PubMed ID: 21354955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; de Herder WW; Krenning EP
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
    Bodei L; Pepe G; Paganelli G
    Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Peptide receptor radionuclide therapy of neuroendocrine tumors].
    Arveschoug AK; Hjorthaug K; Rehling M; Højgaard L; Mortensen J; Oturai PS
    Ugeskr Laeger; 2009 Mar; 171(13):1073. PubMed ID: 19321068
    [No Abstract]   [Full Text] [Related]  

  • 7. Polish experience in Peptide receptor radionuclide therapy.
    Kunikowska J; Królicki L; Sowa-Staszczak A; Hubalewska-Dydejczyk A; Pawlak D; Mikolajczak R; Handkiewicz-Junak D; Szaluś N; Kamiński G; Cwikla J; Jakuciński M; Lukiewicz A; Kowalska A; Gut P
    Recent Results Cancer Res; 2013; 194():467-78. PubMed ID: 22918776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-emitting radionuclides for peptide receptor radionuclide therapy.
    Parus JL; Mikolajczak R
    Curr Top Med Chem; 2012; 12(23):2686-93. PubMed ID: 23339764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors.
    Krenning EP; Teunissen JJ; Valkema R; deHerder WW; deJong M; Kwekkeboom DJ
    J Endocrinol Invest; 2005; 28(11 Suppl International):146-50. PubMed ID: 16625865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms.
    Kaemmerer D; Twrznik M; Kulkarni HR; Hörsch D; Sehner S; Baum RP; Hommann M;
    Ann Surg; 2021 Jul; 274(1):e45-e53. PubMed ID: 33030849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
    Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB
    Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.
    Breeman WA; de Jong M; Kwekkeboom DJ; Valkema R; Bakker WH; Kooij PP; Visser TJ; Krenning EP
    Eur J Nucl Med; 2001 Sep; 28(9):1421-9. PubMed ID: 11585303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
    De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
    Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy: Neuroendocrine cancer--are two radionuclides better than one?
    Kwekkeboom DJ
    Nat Rev Endocrinol; 2012 May; 8(6):326-8. PubMed ID: 22547261
    [No Abstract]   [Full Text] [Related]  

  • 16. Y90 selective internal radiation therapy and peptide receptor radionuclide therapy for the treatment of metastatic neuroendocrine tumors: combination or not?
    Yilmaz E; Engin MN; Özkan ZG; Kovan B; Büyükkaya F; Poyanli A; Sağlam S; Başaran M; Türkmen C
    Nucl Med Commun; 2020 Dec; 41(12):1242-1249. PubMed ID: 32941405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT)].
    Papamichail DG; Exadaktylou PE; Chatzipavlidou VD
    Hell J Nucl Med; 2016; 19(1):75-82. PubMed ID: 27035909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy.
    Van Binnebeek S; Deroose CM; Baete K; Terwinghe C; Vanbilloen B; Koole M; Haustermans K; Mortelmans L; Verslype C; Van Cutsem E; Verbruggen A; Mottaghy FM
    J Clin Oncol; 2011 Jul; 29(19):e579-81. PubMed ID: 21555687
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
    Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
    Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].
    Otte A; Herrmann R; Mäcke HR; Müller-Brand J
    Praxis (Bern 1994); 1999 Aug; 88(31-32):1263-8. PubMed ID: 10479965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.